Spyre Therapeutics, Inc.
SYRE
$15.18
$0.644.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -74.43% | -- | |||
| Gross Profit | 74.43% | -- | |||
| SG&A Expenses | 10.89% | 1.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.55% | 10.58% | |||
| Operating Income | 12.55% | -10.58% | |||
| Income Before Tax | 20.44% | 18.42% | |||
| Income Tax Expenses | -1,600.00% | -94.44% | |||
| Earnings from Continuing Operations | 20.47% | 18.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.47% | 18.44% | |||
| EBIT | 12.55% | -10.58% | |||
| EBITDA | -- | -10.62% | |||
| EPS Basic | -1,627.55% | 102.89% | |||
| Normalized Basic EPS | 27.05% | 24.87% | |||
| EPS Diluted | -1,627.55% | 102.89% | |||
| Normalized Diluted EPS | 27.05% | 24.87% | |||
| Average Basic Shares Outstanding | 9.06% | 8.59% | |||
| Average Diluted Shares Outstanding | 9.06% | 8.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||